Direct-acting antiviral drugs against hepatitis C virus in renal transplant recipients: Is it the dawn of an interferon-free Era?
Direct-acting antiviral drugs against hepatitis C virus in renal transplant recipients: Is it the dawn of an interferon-free Era?
Saudi J Kidney Dis Transpl. 2017 Sep-Oct;28(5):1169-1174
Authors: Rangaswamy D, Nagaraju SP, Attur RP
Abstract
Hepatitis C virus (HCV) is a significant problem among hemodialysis population, especially in India where renal transplant often gets delayed in the presence of live-related donors. An acceleration of liver cirrhosis and poor renal allograft outcomes are often witnessed in allograft recipients with high viral load. Use of interferon in the postrenal transplant setting for the treatment of hepatitis C viral infection was limited to a few grave situations, fearing the precipitation of allograft rejection and poor efficacy for sustained virological remission. However, the availability of newer direct-acting antivirals has opened a new tool box in the management of HCV in the postrenal transplant setting and in reducing the pretransplant waiting period.
PMID: 28937081 [PubMed - in process]
Source: Saudi Journal of Kidney Diseases and Transplantation - Category: Urology & Nephrology Authors: Rangaswamy D, Nagaraju SP, Attur RP Tags: Saudi J Kidney Dis Transpl Source Type: research
More News: Bone Graft | Cirrhosis | Dialysis | Hemodialysis | Hepatitis | Hepatitis C | India Health | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Middle East Health | Saudi Arabia Health | Transplant Surgery | Transplants | Urology & Nephrology | Virology